Viracta Therapeutics Inc expected to post a loss of 31  cents a share - Earnings Preview

Viracta Therapeutics

06/05/2022 12:11

* Viracta Therapeutics Inc  VIRX.OQ   VIRX.O  is expected
to show
no change in quarterly revenue when it reports  results on May
10 (estimated). 
    * ​Refinitiv's mean analyst estimate for Viracta
Therapeutics Inc
is for a loss of 31 cents per share. For the same quarter last
year, the company reported earnings of 35 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 2.4%
in the last three months. ​
    * Wall Street's median 12-month price target for Viracta
Therapeutics Inc is $15​, above​ its last closing price
of $2.53. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.43       -0.43      -0.31     Beat    28.7
 Sep. 30 2021  -0.30       -0.31      -0.40     Missed  -29
 Jun. 30 2021  -0.24       -0.24      -0.25     Missed  -5.6​
 Mar. 31 2021  0.03        -0.21      0.35      Beat    266.7
 ​​Dec.        -0.96       -0.96      -0.73     Beat    23.6
 31 2020                                                
 Sep. 30 2020  -1.21       -1.18      -1.01     Beat    13.9​
 Jun. 30 2020  -1.87       -1.94      -2.10     Missed  -8.1
 Mar. 31 2020  -2.41       -2.44      -1.75     Beat    28.3
 This summary was machine generated May 6 at 11:11 GMT.  All
figures in US dollars  unless otherwise stated